According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
List view / Grid view
Researchers have shown how the MIS hormone can prevent ovulation in females, making it a potential new form of contraception.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
A new study in cell cultures has shown that the sanguinarine plant compound could be used to treat people with triple-negative breast cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Scientists have created an assay to detect the protein cathepsin B in blood, a biomarker for a range of diseases.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
Scientists have shown that culturing cells with a modified serum could allow drugs to be screened for toxicity earlier during research.
Researchers have elucidated the 3D structure of the Taspase 1 enzyme, known to be involved in a range of cancers.
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.